November 9, 2020
Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues, SITC 2020
Download the poster
You might also be interested by
CellTalk
Landmark study on metastatic breast cancer highlights the importance of identifying HER2-low patients
June 23, 2022
Proteomics/Mass Spectrometry
More infoPress Releases
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
May 19, 2022
Proteomics/Mass Spectrometry
More infoBrochures
High Performance Technologies for Cytokine Measurement
November 8, 2021
Immune Monitoring
More info